TAIZHOU, China, March 16,
2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc.
(NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty
pharmaceutical company focusing on the research, development,
manufacturing, marketing, and sales of Traditional Chinese Medicine
Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and
After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM
Homologous Supplements ("TCMHS") announced today that a fund
granted to the Company for the key techniques incorporated into
advanced Directly-Oral TCMPs derived from agriculture has
been approved on February 19,
2020, by the Hailing District Science and Technology
Bureau of Taizhou city.
The grant is founded by the Scientific and Technologic
Development Program of Hailing District and supported by the
Hailing District government. Our project is about the
development of the key technologies used in medical herb planting
pre-processing of raw materials for Directly-Oral TCMP products.
The Company will develop a one-stop
system from medical herb planting to the finished products of
TCMPs, which enables the Company to track and ensure products'
qualities. The Company is expected to further its lead on research
and development of specialized Advanced TCMPs and receive
additional benefits when marketing its new Advanced TCMP products
in the future.
Dr. Jing-Zhen Deng, Chief
Scientific Officer and Chief Operating Officer of China SXT,
commented, "This grant supported by the local government
can contribute to our
continuous effort in leading research and development of new
advanced TCMPs and chase of higher quality of the products. We
believe it will further strengthen our R&D capabilities in our
new Advanced TCMPs, which is expected to eventually help expanding
our market share in our advanced Directly-Oral TCMP
products."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the
international markets the Company serves and assumptions underlying
or related to any of the foregoing and other risks contained in
reports filed by the Company with the Securities and Exchange
Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward - looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company:
Dr. Jing-Zhen Deng, COO &
CSO
Email: jdeng@sxtchina.com or ir@sxtchina.com
Phone: 86-523-8629-9028
View original
content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-announces-that-it-received-a-grant-supported-by-city-government-301024801.html
SOURCE China SXT Pharmaceuticals, Inc.